$VIR News

Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Vir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026 - Slideshow

Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combination To Treat Chronic Hepatitis Delta

Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript

Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY.

Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth

Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

A Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial Milestone

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Vir Biotech Doses First Patient In Phase 1 Expansion Trial Of VIR-5500 For Metastatic Prostate Cancer

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000

Vir Biotechnology (VIR) Leading with Its BiTEs Therapy

VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick

Vir Biotechnology CEO Marianne De Backer To Additional Role Of President, Effective Immediately